ArticleMolecular imaging and biology2026
LLM-Enhanced Multimodal Fusion of SPECT Radiomics and Clinical Data for Predicting 131I Therapeutic Response in Differentiated Thyroid Cancer.
Article in Molecular imaging and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPatients with differentiated thyroid cancer (DTC) treated with radioactive iodine (RAI) remain at risk of adverse outcomes. Early prediction of RAI efficacy is critical for optimizing clinical management. PURPOSE: To develop a model integrating Single Photon Emission Computed Tomography (SPECT) radiomic features and clinical variables for predicting the therapeutic efficacy of 131I treatment in patients with DTC. MATERIALS AND
methodThe SPECT images and clinical data from 311 patients were included in this study. A total of 1,688 radiomic features were extracted from SPECT images. We investigated the diagnostic performance of 30 cross-combined models. Radiomic features were then combined with clinical parameters using early-fusion and late-fusion strategies. To further enhance predictive performance, an input sequence reflecting the selected features and the prediction task was designed and fed into a selected Large Language Model (LLM), which was fine-tuned using low-rank adaptation to optimize fused feature representations. Model performance was evaluated using accuracy (Acc), sensitivity (Sens), positive predictive value (PPV), F1-score, and the area under the curve (AUC).
resultsThe Relief-F + random forest radiomic model achieved the highest AUC (0.69). Multimodal models combining radiomics with clinical features outperformed clinical-only models, demonstrating the added predictive value of radiomics. The final LLM-enhanced multimodal model achieved the best performance, with an AUC of 0.85 and notable improvements in sensitivity and F1-score.
conclusionsThe proposed multimodal framework provides accurate early prediction of RAI therapeutic response in DTC and holds promise for improving individualized treatment planning and follow-up strategies.
Indexed as
Identifiers
42420643What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.